StockData
Pharming Group N.V. logo

Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30
$12.06−0.53 (-4.21%)

Close on Nov 17, 2026Market cap $846.23MP/E 301.5Yield –

Pharming r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $100.37M, up 20.7% from the year before. The highest annual figure on record is $100.37M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$100.37M+20.7%
FY2024Dec 31, 2024$83.15M+20.7%
FY2023Dec 31, 2023$68.91M+31.2%
FY2022Dec 31, 2022$52.53M-25.3%
FY2021Dec 31, 2021$70.37M+82.7%
FY2020Dec 31, 2020$38.52M+21.2%
FY2019Dec 31, 2019$31.79M–

More Pharming figures

See a number that looks wrong?